Ciarán Campbell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ciarán Campbell has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Gianpiero L. Cavalleri
School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland
2 shared publications Holger Lerche
Department of Neurology & Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
2 shared publicationsAnne Molloy
Department of Medical Gerontology, School of Medicine, Trinity College Dublin, Dublin 2, Republic of Ireland
1 shared publicationBerge A. Minassian
Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, Canada
1 shared publicationBobby P. Koeleman
Division of Neurosciences Universitair Medisch Centrum Utrecht Utrecht The Netherlands
1 shared publicationCaragh Stapleton
Department of Pharmacy and Biomolecular Science RCSI Dublin Dublin Ireland
1 shared publication
Latest Publications
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A5834
Prevalence of Fatigue and Sleepiness in a Post-Covid Clinic
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A5834
Prevalence of Fatigue and Sleepiness in a Post-Covid Clinic
- Open Access
- 6 June 2022
- Published by Elsevier in EBioMedicine
- Vol. 81, 104098
The role of common genetic variation in presumed monogenic epilepsies
- 6 June 2022
- Published by Elsevier in EBioMedicine
- Vol. 81, 104098
Open AccessThe role of common genetic variation in presumed monogenic epilepsies
- Open Access
A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam
Objective: Levetiracetam (LEV) is an effective antiseizure medicine, but 10%–20% of people treated with LEV report psychiatric side‐effects, and up to 1% may have psychotic episodes. Pharmacogenomic predictors of these adverse drug reactions (ADRs) have yet to be identified. We sought to determine the contribution of both common and rare genetic variation to psychiatric and behavioral ADRs associated with LEV.Methods: This case‐control study compared cases of LEV‐associated behavioral disorder (n = 149) or psychotic reaction (n = 37) to LEV‐exposed people with no history of psychiatric ADRs (n = 920). All samples were of European ancestry. We performed genome‐wide association study (GWAS) analysis comparing those with LEV ADRs to controls. We estimated the polygenic risk scores (PRS) for schizophrenia and compared cases with LEV‐associated psychotic reaction to controls. Rare variant burden analysis was performed using exome sequence data of cases with psychotic reactions (n = 18) and controls (n = 122).Results: Univariate GWAS found no significant associations with either LEV‐associated behavioural disorder or LEV‐psychotic reaction. PRS analysis showed that cases of LEV‐associated psychotic reaction had an increased PRS for schizophrenia relative to contr ols (p = .0097, estimate = .4886). The rare‐variant analysis found no evidence of an increased burden of rare genetic variants in people who had experienced LEV‐associated psychotic reaction relative to controls.Significance: The polygenic burden for schizophrenia is a risk factor for LEV‐associated psychotic reaction. To assess the clinical utility of PRS as a predictor, it should be tested in an independent and ideally prospective cohort. Larger sample sizes are required for the identification of significant univariate common genetic signals or rare genetic signals associated with psychiatric LEV ADRs.
Open AccessA pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam
Objective: Levetiracetam (LEV) is an effective antiseizure medicine, but 10%–20% of people treated with LEV report psychiatric side‐effects, and up to 1% may have psychotic episodes. Pharmacogenomic predictors of these adverse drug reactions (ADRs) have yet to be identified. We sought to determine the contribution of both common and rare genetic variation to psychiatric and behavioral ADRs associated with LEV.Methods: This case‐control study compared cases of LEV‐associated behavioral disorder (n = 149) or psychotic reaction (n = 37) to LEV‐exposed people with no history of psychiatric ADRs (n = 920). All samples were of European ancestry. We performed genome‐wide association study (GWAS) analysis comparing those with LEV ADRs to controls. We estimated the polygenic risk scores (PRS) for schizophrenia and compared cases with LEV‐associated psychotic reaction to controls. Rare variant burden analysis was performed using exome sequence data of cases with psychotic reactions (n = 18) and controls (n = 122).Results: Univariate GWAS found no significant associations with either LEV‐associated behavioural disorder or LEV‐psychotic reaction. PRS analysis showed that cases of LEV‐associated psychotic reaction had an increased PRS for schizophrenia relative to contr ols (p = .0097, estimate = .4886). The rare‐variant analysis found no evidence of an increased burden of rare genetic variants in people who had experienced LEV‐associated psychotic reaction relative to controls.Significance: The polygenic burden for schizophrenia is a risk factor for LEV‐associated psychotic reaction. To assess the clinical utility of PRS as a predictor, it should be tested in an independent and ideally prospective cohort. Larger sample sizes are required for the identification of significant univariate common genetic signals or rare genetic signals associated with psychiatric LEV ADRs.